Insiders BridgeBio Pharma, Inc.

Equities

Real-time Estimate Cboe BZX Other stock markets 10:20:55 2024-07-05 am EDT			5-day change	1st Jan Change
24.86 ^USD	-0.54%		-2.05%	-38.54%

Jun. 18	BridgeBio Surpasses Interim Analysis Enrollment Target in Limb-Girdle Muscular Dystrophy Trial	MT
Jun. 18	BridgeBio Pharma, Inc. Surpasses Interim Analysis Enrollment Target and Receives U.S. FDA Rare Pediatric Disease Designation for BBP-418, a Potential Treatment for Limb-Girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9)	CI

Bridgebio Pharma Insider Sold Shares Worth $4,206,000, According to a Recent SEC Filing	Dec. 28	MT
Bridgebio Pharma Insider Sold Shares Worth $1,500,038, According to a Recent SEC Filing	Nov. 20	MT
Bridgebio Pharma Insider Sold Shares Worth $660,059, According to a Recent SEC Filing	Nov. 20	MT
Insider Sell: Bridgebio Pharma	23-08-18	MT
Insider Sell: Bridgebio Pharma	23-08-18	MT
Insider Sell: Bridgebio Pharma	23-05-18	MT
Insider Sell: Bridgebio Pharma	23-05-18	MT
Insider Sell: Bridgebio Pharma	23-05-05	MT
Insider Sell: Bridgebio Pharma	23-05-05	MT
Insider Sell: BridgeBio Pharma	23-03-06	MT
BridgeBio Pharma, Inc. Announces Board and Committee Changes	23-02-23	CI
Insider Sell: BridgeBio Pharma	23-02-07	MT
BridgeBio Pharma Executive to Join Atai Life Sciences as CFO	22-06-17	MT
Insider Buy: Bridgebio Pharma	22-01-04	MT
Bridgebio Pharma, Inc. Appoints Hannah Valantine to Its Board of Directors	21-10-25	CI
BridgeBio Pharma, Inc Announces Board Appointments	21-08-24	CI
BridgeBio Pharma, Inc. Announces Executive Changes	21-01-04	CI
Bridgebio Pharma Announces the Resignation of Brian Stolz as Chief Operating Officer of the Company	20-10-23	CI
BridgeBio Pharma, Inc. Announces Board Appointments	20-06-24	CI
BridgeBio Pharma, Inc. Appoints Ronald J. Daniels to the Board	20-02-19	CI

No results for this search